Expression of Multiple Cancer/Testis Genes in Several Breast Cancer Cell Lines

Document Type : Original Article (s)

Authors

1 Molecular Medicine Group, Biotechnology Research Centre, Pasteur Institute of Iran AND Department of Biology, School of Science, Islamic Azad University, Science and Research Branch, Tehran, Iran

2 Molecular Medicine Group, Biotechnology Research Centre, Pasteur Institute of Iran, Tehran, Iran

3 Assistant Professor, Cancer Genetics Research Group, Breast Cancer Research Center (BCRC), Tehran, Iran

4 PhD Student Cancer Genetics Research Group, Breast Cancer Research Center (BCRC), Tehran, Iran

5 Assistant Professor, Molecular Medicine Group, Biotechnology research Centre, Pasteur Institute of Iran, Tehran, Iran

Abstract

Background: Cancer-Testis genes (CT-genes) are a gene family that only expressed in normal testis tissue and some of them are randomly expressed in some types of cancers. These genes can be promising cases for immunotherapy of breast cancer. This research was carried out for comparison of the expression frequencies these genes in cancerous cell lines and tumor samples.Methods: In this analytical-descriptive study, after providing three breast-cancer cell lines and their cultures in appropriate medium, RNA extraction and cDNA synthesis were done and expressions of NY-ESO-1 1a, NY-ESO-1 1b, SCP1, SSX-2 and MAGE-3 genes were studied using multiplex real time-polymerase chain reaction (multiplex RT-PCR) method.Findings: None of cell lines expressed Cancer-Testis genes; but all of them expressed glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene (internal control).Conclusion: According to the role of these genes in gametogenesis, we can consider that their expressions in cancer cells are based on dedifferentiation. The observed difference between expression frequency of these genes in breast-cancer cell lines and tumor samples can be related to several passages which are carried out for providing cell lines. By examining more cell lines of breast cancer for these genes, we can achieve more accurate results.

Keywords

References

  1. Zendman AJ, Ruiter DJ, Van Muijen GN. Cancer/testis-associated genes: identification, expression profile, and putative function. J Cell Physiol 2003; 194(3): 272-88.
  2. Caballero OL, Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 2009; 100(11): 2014-21.
  3. Kalejs M, Erenpreisa J. Cancer/testis antigens and gametogenesis: a review and "brain-storming" session. Cancer Cell Int 2005; 5(1): 4.
  4. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005; 5(8): 615-25.
  5. Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immun 2004; 4: 1.
  6. Meklat F, Li Z, Wang Z, Zhang Y, Zhang J, Jewell A, et al. Cancer-testis antigens in haematological malignancies. Br J Haematol 2007; 136(6): 769-76.
  7. Parmigiani RB, Bettoni F, Vibranovski MD, Lopes MH, Martins WK, Cunha IW, et al. Characterization of a cancer/testis (CT) antigen gene family capable of eliciting humoral response in cancer patients. Proc Natl Acad Sci U S A 2006; 103(48): 18066-71.
  8. Wadle A, Kubuschok B, Imig J, Wuellner B, Wittig C, Zwick C, et al. Serological immune response to cancer testis antigens in patients with pancreatic cancer. Int J Cancer 2006; 119(1): 117-25.
  9. Mischo A, Kubuschok B, Ertan K, Preuss KD, Romeike B, Regitz E, et al. Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer. Int J Cancer 2006; 118(3): 696-703.
  10. Costa FF, Le BK, Brodin B. Concise review: cancer/testis antigens, stem cells, and cancer. Stem Cells 2007; 25(3): 707-11.
  11. Atanackovic D, Arfsten J, Cao Y, Gnjatic S, Schnieders F, Bartels K, et al. Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood 2007; 109(3): 1103-12.
  12. Chen YT, Scanlan MJ, Sahin U, Tureci O, Gure AO, Tsang S, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A 1997; 94(5): 1914-8.
  13. Bertram J, Palfner K, Hiddemann W, Kneba M. Elevated expression of S100P, CAPL and MAGE 3 in doxorubicin-resistant cell lines: comparison of mRNA differential display reverse transcription-polymerase chain reaction and subtractive suppressive hybridization for the analysis of differential gene expression. Anticancer Drugs 1998; 9(4): 311-7.
  14. Glynn SA, Gammell P, Heenan M, O'Connor R, Liang Y, Keenan J, et al. A new superinvasive in vitro phenotype induced by selection of human breast carcinoma cells with the chemotherapeutic drugs paclitaxel and doxorubicin. Br J Cancer 2004; 91(10): 1800-7.
  15. Cronwright G, Le BK, Gotherstrom C, Darcy P, Ehnman M, Brodin B. Cancer/testis antigen expression in human mesenchymal stem cells: down-regulation of SSX impairs cell migration and matrix metalloproteinase 2 expression. Cancer Res 2005; 65(6): 2207-15.
  16. Old LJ. Cancer is a somatic cell pregnancy. Cancer Immun 2007; 7: 19.
  17. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58(2): 71-96.
  18. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006; 24(33): 5313-27.
  19. Mashino K, Sadanaga N, Tanaka F, Yamaguchi H, Nagashima H, Inoue H, et al. Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas. Br J Cancer 2001; 85(5): 713-20.
  20. Sugita Y, Wada H, Fujita S, Nakata T, Sato S, Noguchi Y, et al. NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors. Cancer Res 2004; 64(6): 2199-204.
  21. Curigliano G, Viale G, Ghioni M, Jungbluth AA, Bagnardi V, Spagnoli GC, et al. Cancer-testis antigen expression in triple-negative breast cancer. Ann Oncol 2011; 22(1): 98-103.
  22. Grigoriadis A, Caballero OL, Hoek KS, da SL, Chen YT, Shin SJ, et al. CT-X antigen expression in human breast cancer. Proc Natl Acad Sci U S A 2009; 106(32): 13493-8.
  23. Matkovic B, Juretic A, Spagnoli GC, Separovic V, Gamulin M, Separovic R, et al. Expression of MAGE-A and NY-ESO-1 cancer/testis antigens in medullary breast cancer: retrospective immunohistochemical study. Croat Med J 2011; 52(2): 171-7.
  24. Hussein YM, Gharib AF, Etewa RL, El-Shal AS, Abdel-Ghany ME, Elsawy WH. The melanoma-associated antigen-A3, -A4 genes: relation to the risk and clinicopathological parameters in breast cancer patients. Mol Cell Biochem 2011; 351(1-2): 261-8.
  25. Russo V, Traversari C, Verrecchia A, Mottolese M, Natali PG, Bordignon C. Expression of the MAGE gene family in primary and metastatic human breast cancer: implications for tumor antigen-specific immunotherapy. Int J Cancer 1995; 64(3): 216-21.
  26. Koslowski M, Bell C, Seitz G, Lehr HA, Roemer K, Muntefering H, et al. Frequent nonrandom activation of germ-line genes in human cancer. Cancer Res 2004; 64(17): 5988-93.
  27. De Smet C, Lurquin C, Lethe B, Martelange V, Boon T. DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol Cell Biol 1999; 19(11): 7327-35.
  28. De Smet C, Loriot A, Boon T. Promoter-dependent mechanism leading to selective hypomethylation within the 5' region of gene MAGE-A1 in tumor cells. Mol Cell Biol 2004; 24(11): 4781-90.
Journal of Isfahan Medical School
Volume 32, Issue 273 - Serial Number 273
January and February 2014
Pages 50-58

Files

History

  • Receive Date: 16 October 2013
  • Revise Date: 30 April 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics